Autism Spectrum Disorder Clinical Trials

Find Autism Spectrum Disorder Clinical Trials Near You

Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test, Behavioral
Study Type: Observational
SUMMARY

This observational study aims to evaluate how patterns of behavioral and sensorimotor responses measured using the BlinkLab Dx1 smartphone application relate to autism diagnoses in children ages 2 to 11. BlinkLab Dx1 is a non-invasive, smartphone-based application under development as a diagnostic aid for healthcare providers assessing autism. In this study, children who have undergone a neurodevelopmental assessment within the past 12 months will complete two short, video-based sessions using the BlinkLab Dx1 app. The app presents visual and auditory stimuli and records reflexive sensorimotor responses and patterns of repetitive behavior. Additionally, primary caregivers will answer a short questionnaire in the app about symptoms and development. Information about prior neurodevelopmental assessments, including documented DSM-5-based diagnoses from routine clinical practice, will be collected retrospectively. The study will examine how the app's neurobehavioral measurements relate to previously assigned clinical diagnoses. These paired data will be used to develop and evaluate a machine learning-based algorithm using separate training and testing datasets to assess whether patterns measured by BlinkLab Dx1 can help distinguish children with autism from children without an autism diagnosis. This study does not involve any treatment or medical intervention.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 11
Healthy Volunteers: t
View:

• Age: Children between 2 to 11 years old

• Parent/Caregiver/Healthcare Provider Concern: The child has received a diagnostic outcome of a neurodevelopmental assessment based on DSM-5 criteria within the past 12 months.

• Language Proficiency: Parents and subjects must have functional English capability in the home environment.

• Informed Consent: Parents must be able to read, understand, and voluntarily sign the Informed Consent Form (ICF).

• Videotaping: subjects must be willing to be videotaped during the diagnostic assessment by the BlinkLab App.

Locations
United States
New Jersey
Remote study conducted nationwide; all participation occurs via smartphone app at home.
RECRUITING
Princeton
Contact Information
Primary
Myrthe J. Ottenhoff, MD, PhD
study@blinklab.org
908-824-3471
Time Frame
Start Date: 2025-02-15
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 1000
Treatments
Model Development Group - Children evaluated for neurodevelopmental conditions.
Children aged 2-11 who have formally been evaluated for neurodevelopmental conditions in the 12 months prior to the enrollment date. This includes children with and without autism, children with other neurodevelopmental conditions and children eventually not diagnosed with any neurodevelopmental condition.
Model Testing Group - Children evaluated for neurodevelopmental conditions.
Children aged 2-11 who have formally been evaluated for neurodevelopmental conditions in the 12 months prior to the enrollment date. This includes children with and without autism, children with other neurodevelopmental conditions and children eventually not diagnosed with any neurodevelopmental condition. Data collection for this group is blinded.
Related Therapeutic Areas
Sponsors
Leads: Blinklab Limited

This content was sourced from clinicaltrials.gov